A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus

Change in fasting plasma glucose(FPG)

Change from baseline in fasting plasma glucose (FPG) after 16 weeks of treatment

Time frame: From baseline (week 0) to week 16

Weekly doses of GZR4 Injection/Insulin Degludec

Weekly doses of once-weekly GZR4 Injection and once-daily Insulin Degludec Injection from week 15 to week 16 are presented.

Time frame: Week 15-16

Incidence and Rate of Treatment-emergent adverse events (TEAEs)

A TEAE is defined as an event that had onset date (or increase in severity) during the on-treatment observation period.

Time frame: From baseline (week 0) to week 20

Incidence and Rate of hypoglycemia episodes

Hypoglycaemia alert episodes (level 1) are defined as episodes that are sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy with plasma glucose value of equal to or above (\>=) 3.0 and less than (\<) 3.9 mmol/L (\>= 54 and \< 70 mg/dL) confirmed by blood glucose (BG) meter. Clinically significant hypoglycaemic episodes (level 2) are defined as episodes that are sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) are defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Severe hypoglycaemic episodes (level 3) are defined as episodes that are associated with severe cognitive impairment requiring external assistance for recovery.

Time frame: From baseline (week 0) to week 20